1
|
Kongsompong S, E-kobon T, Taengphan W, Sangkhawasi M, Khongkow M, Chumnanpuen P. Computer-Aided Virtual Screening and In Vitro Validation of Biomimetic Tyrosinase Inhibitory Peptides from Abalone Peptidome. Int J Mol Sci 2023; 24:ijms24043154. [PMID: 36834568 PMCID: PMC9965614 DOI: 10.3390/ijms24043154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Revised: 02/02/2023] [Accepted: 02/02/2023] [Indexed: 02/09/2023] Open
Abstract
Hyperpigmentation is a medical and cosmetic problem caused by an excess accumulation of melanin or the overexpression of the enzyme tyrosinase, leading to several skin disorders, i.e., freckles, melasma, and skin cancer. Tyrosinase is a key enzyme in melanogenesis and thus a target for reducing melanin production. Although abalone is a good source of bioactive peptides that have been used for several properties including depigmentation, the available information on the anti-tyrosinase property of abalone peptides remains insufficient. This study investigated the anti-tyrosinase properties of Haliotis diversicolor tyrosinase inhibitory peptides (hdTIPs) based on mushroom tyrosinase, cellular tyrosinase, and melanin content assays. The binding conformation between peptides and tyrosinase was also examined by molecular docking and dynamics study. KNN1 showed a high potent inhibitory effect on mushroom tyrosinase with an IC50 of 70.83 μM. Moreover, our selected hdTIPs could inhibit melanin production through the reductions in tyrosinase activity and reactive oxygen species (ROS) levels by enhancing the antioxidative enzymes. RF1 showed the highest activity on both cellular tyrosinase inhibition and ROS reduction. leading to the lower melanin content in B16F10 murine melanoma cells. Accordingly, it can be assumed that our selected peptides exhibited high potential in medical cosmetology applications.
Collapse
Affiliation(s)
- Sasikarn Kongsompong
- Interdisciplinary Graduate Program in Bioscience, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand
| | - Teerasak E-kobon
- Department of Genetics, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand
- Omics Center for Agriculture, Bioresources, Food and Health, Kasetsart University (OmiKU), Bangkok 10900, Thailand
| | - Weerasak Taengphan
- Expert Centre of Innovative Herbal Products (InnoHerb), Thailand Institute of Scientific and Technological Research, Techno Polis, Khlong Luang District, Pathum Thani 12120, Thailand
| | - Mattanun Sangkhawasi
- Program in Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand
| | - Mattaka Khongkow
- National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand
| | - Pramote Chumnanpuen
- Omics Center for Agriculture, Bioresources, Food and Health, Kasetsart University (OmiKU), Bangkok 10900, Thailand
- Department of Zoology, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand
- Correspondence:
| |
Collapse
|
2
|
Panda MK, Paul M, Singdevsachan SK, Tayung K, Das SK, Thatoi H. Promising Anti-cancer Therapeutics From Mushrooms: Current Findings and Future Perceptions. Curr Pharm Biotechnol 2021; 22:1164-1191. [PMID: 33032507 DOI: 10.2174/1389201021666201008164056] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 09/02/2020] [Accepted: 09/03/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Nowadays, medicines derived from natural sources have drawn much attention as potential therapeutic agents in the suppression and treatment of cancer because of their low toxicity and fewer side effects. OBJECTIVE The present review aims to assess the currently available knowledge on the ethnomedicinal uses and pharmacological activities of bioactive compounds obtained from medicinal mushrooms towards cancer treatment. METHODS A literature search has been conducted for the collection of research papers from universally accepted scientific databases. These research papers and published book chapters were scrutinized to retrieve information on ethnomedicinal uses of mushrooms, different factors involved in cancer cell proliferation, clinical and in silico pharmaceutical studies made for possible treatments of cancer using mushroom derived compounds. Overall, 241 articles were retrieved and reviewed from the year 1970 to 2020, out of which 98 relevant articles were finally considered for the preparation of this review. RESULTS This review presents an update on the natural bioactive substances derived from medicinal mushrooms and their role in inhibiting the factors responsible for cancer cell proliferation. Along with it, the present review also provides information on the ethnomedicinal uses, solvents used for extraction of anti-cancer metabolites, clinical trials, and in silico studies that were undertaken towards anticancer drug development from medicinal mushrooms. CONCLUSION The present review provides extensive knowledge on various anti-cancer substances obtained from medicinal mushrooms, their biological actions, and in silico drug designing approaches, which could form a basis for the development of natural anti-cancer therapeutics.
Collapse
Affiliation(s)
- Mrunmaya K Panda
- Department of Biotechnology, North Orissa University, Baripada-757003, Odisha, India
| | - Manish Paul
- Department of Biotechnology, North Orissa University, Baripada-757003, Odisha, India
| | - Sameer K Singdevsachan
- Spinco Biotech Pvt. Ltd., Spinco Towers, No. 934, 5th A cross, Service Road, HRBR Layout 1st Block, Kalyan Nagar, Bengaluru-560043, Karnataka, India
| | - Kumananda Tayung
- Department of Botany, Gauhati University, Gopinath Bordoloi Nagar, Guwahati-781014, Assam, India
| | - Swagat K Das
- Department of Biotechnology, College of Engineering and Technology, Biju Patnaik University of Technology, Bhubaneswar- 751003, Odisha, India
| | - Hrudayanath Thatoi
- Department of Biotechnology, North Orissa University, Baripada-757003, Odisha, India
| |
Collapse
|
3
|
Niego AG, Rapior S, Thongklang N, Raspé O, Jaidee W, Lumyong S, Hyde KD. Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value. J Fungi (Basel) 2021; 7:397. [PMID: 34069721 PMCID: PMC8161071 DOI: 10.3390/jof7050397] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 05/16/2021] [Accepted: 05/16/2021] [Indexed: 02/06/2023] Open
Abstract
Macrofungi production and economic value have been increasing globally. The demand for macrofungi has expanded rapidly owing to their popularity among consumers, pleasant taste, and unique flavors. The presence of high quality proteins, polysaccharides, unsaturated fatty acids, minerals, triterpene sterols, and secondary metabolites makes macrofungi an important commodity. Macrofungi are well known for their ability to protect from or cure various health problems, such as immunodeficiency, cancer, inflammation, hypertension, hyperlipidemia, hypercholesterolemia, and obesity. Many studies have demonstrated their medicinal properties, supported by both in vivo and in vitro experimental studies, as well as clinical trials. Numerous bioactive compounds isolated from mushrooms, such as polysaccharides, proteins, fats, phenolic compounds, and vitamins, possess strong bioactivities. Consequently, they can be considered as an important source of nutraceuticals. Numerous edible mushrooms have been studied for their bioactivities, but only a few species have made it to the market. Many species remain to be explored. The converging trends and popularity of eastern herbal medicines, natural/organic food product preference, gut-healthy products, and positive outlook towards sports nutrition are supporting the growth in the medicinal mushroom market. The consumption of medicinal mushrooms as functional food or dietary supplement is expected to markedly increase in the future. The global medicinal mushroom market size is projected to increase by USD 13.88 billion from 2018 to 2022. The global market values of promising bioactive compounds, such as lentinan and lovastatin, are also expected to rise. With such a market growth, mushroom nutraceuticals hold to be very promising in the years to come.
Collapse
Affiliation(s)
- Allen Grace Niego
- Center of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand; (A.G.N.); (N.T.); (O.R.)
- School of Science, Mae Fah Luang University, Chiang Rai 57100, Thailand
- Iloilo Science and Technology University, La Paz, Iloilo 5000, Philippines
| | - Sylvie Rapior
- Laboratory of Botany, Phytochemistry and Mycology, Faculty of Pharmacy, CEFE, CNRS, University Montpellier, EPHE, IRD, CS 14491, 15 Avenue Charles Flahault, CEDEX 5, 34093 Montpellier, France;
| | - Naritsada Thongklang
- Center of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand; (A.G.N.); (N.T.); (O.R.)
- School of Science, Mae Fah Luang University, Chiang Rai 57100, Thailand
| | - Olivier Raspé
- Center of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand; (A.G.N.); (N.T.); (O.R.)
- School of Science, Mae Fah Luang University, Chiang Rai 57100, Thailand
| | - Wuttichai Jaidee
- Medicinal Plants Innovation Center, Mae Fah Luang University, Chiang Rai 57100, Thailand;
| | - Saisamorn Lumyong
- Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand;
- Research Center of Microbial Diversity and Sustainable Utilization, Chiang Mai University, Chiang Mai 50200, Thailand
- Academy of Science, The Royal Society of Thailand, Bangkok 10300, Thailand
| | - Kevin D. Hyde
- Center of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand; (A.G.N.); (N.T.); (O.R.)
- Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand;
- Innovative Institute of Plant Health, Zhongkai University of Agriculture and Engineering, Guangzhou 510408, China
| |
Collapse
|
4
|
Ismaya WT, Tjandrawinata RR, Rachmawati H. Prediction of the Mannose-Binding Site in the Agaricus bisporus Mannose-Binding Protein. Protein J 2021; 40:554-561. [PMID: 33959874 DOI: 10.1007/s10930-021-09993-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/28/2021] [Indexed: 11/29/2022]
Abstract
Agaricus bisporus mannose-binding protein (Abmb) was discovered as part of mushroom tyrosinase (PPO3) complex. Apart from its presence, nothing is known about its function or activity in the mushroom. The protein is evolutionarily related to lectins with β-trefoil fold, which are glucose or galactose (and their derivatives) binding proteins. Abmb is also recently showed to display the typical agglutination activity of lectin when in complex with PPO3; this further supports Abmb similarity to its structural homologs from lectin with β-trefoil fold. However, Abmb has no affinity towards glucose or galactose but for mannose, thus its binding to the sugar may be different from its homologs. To date, the natural ligand of Abmb is unknown and the structure of Abmb in the presence of a ligand is not available. Therefore, the mannose-binding site of Abmb was predicted using molecular docking, which was consulted with the information from its structural homologs. This conservative approach would prevent over-speculation. The mannose-binding site of Abmb is likely located in the same region to that of Abmb structural homologs but with a shift in position due to the presence of additional surface loop. In addition, benefiting from the information from an in vitro study on Abmb sugar specificity, the mannose poses suggested that the sugar might interact with the side chains of Arg15, Thr45, Gln48, Asp49, Asp51 and Arg51. Most of these residues were equally present in Abmb structural homologs despite variation of their positions in the amino acid sequence. The variation probably originates from alteration of its amino acid sequence during evolution.
Collapse
Affiliation(s)
- Wangsa Tirta Ismaya
- Dexa Laboratories of Biomolecular Sciences, Industri Selatan V, PP-7, 17550, Cikarang, Indonesia.
| | | | - Heni Rachmawati
- Research Group of Pharmaceutics, School of Pharmacy, Bandung Institute of Technology, Ganesa 10, 40132, Bandung, Indonesia. .,Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology, Ganesa 10, 40132, Bandung, Indonesia.
| |
Collapse
|
5
|
Tirta Ismaya W, Tjandrawinata RR, Rachmawati H. Lectins from the Edible Mushroom Agaricus bisporus and Their Therapeutic Potentials. Molecules 2020; 25:E2368. [PMID: 32443732 PMCID: PMC7287795 DOI: 10.3390/molecules25102368] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2020] [Revised: 05/09/2020] [Accepted: 05/09/2020] [Indexed: 01/02/2023] Open
Abstract
The mushroom Agaricus bisporus secretes biologically active compounds and proteins with benefits for human health. Most reported proteins from A. bisporus are tyrosinases and lectins. Lectins are of therapeutic or pharmaceutical interest. To date, only limited information is available on A. bisporus lectins and lectin-like proteins. No therapeutic products derived from A. bisporus lectin (ABL) are available on the market despite its extensive exploration. Recently, A. bisporus mannose-binding protein (Abmb) was discovered. Its discovery enriches the information and increases the interest in proteins with therapeutic potential from this mushroom. Furthermore, the A. bisporus genome reveals the possible occurrence of other lectins in this mushroom that may also have therapeutic potential. Most of these putative lectins belong to the same lectin groups as ABL and Abmb. Their relationship is discussed. Particular attention is addressed to ABL and Abmb, which have been explored for their potential in medicinal or pharmaceutical applications. ABL and Abmb have anti-proliferative activities toward cancer cells and a stimulatory effect on the immune system. Possible scenarios for their use in therapy and modification are also presented.
Collapse
Affiliation(s)
- Wangsa Tirta Ismaya
- Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Industri Selatan V PP-7, Jababeka 2, Cikarang 17550, Indonesia; (W.T.I.); (R.R.T.)
| | - Raymond Rubianto Tjandrawinata
- Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Industri Selatan V PP-7, Jababeka 2, Cikarang 17550, Indonesia; (W.T.I.); (R.R.T.)
| | - Heni Rachmawati
- School of Pharmacy, Bandung Institute of Technology, Ganesha 10, Bandung 40132, Indonesia
- Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology, Ganesha 10, Bandung 40132, Indonesia
| |
Collapse
|
6
|
Agaricus bisporus mannose binding protein is not an agglutinating protein. Biochem Biophys Res Commun 2019; 519:773-776. [PMID: 31547987 DOI: 10.1016/j.bbrc.2019.09.071] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2019] [Accepted: 09/17/2019] [Indexed: 11/21/2022]
Abstract
Agaricus bisporus mannose binding protein (Abmb) demonstrates permeability to epithelial monolayer barrier of the intestine, resistance to gastrointestinal tract conditions and to proteolysis therefore it holds potential as a drug carrier for oral route administration. Abmb also display antiproliferative activity to breast cancer cells and stimulation of immune system thus could potentially be also developed for therapeutic purpose. It is not immunogenic or toxic thereby safe for use. In this paper we further provide evidence that Abmb also lacks of agglutinating activity despite sharing high structural homology to lectins. Abmb is thereby the only mannose specific binding protein that is not member of lectin family. This evidence provides further support on the use of Abmb as pharmaceutical or medicinal agent. Its molecular globularity that may contribute to its lack of agglutination capacity was also evaluated.
Collapse
|
7
|
Barros MR, Menezes TM, da Silva LP, Pires DS, Princival JL, Seabra G, Neves JL. Furan inhibitory activity against tyrosinase and impact on B16F10 cell toxicity. Int J Biol Macromol 2019; 136:1034-1041. [DOI: 10.1016/j.ijbiomac.2019.06.120] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 05/03/2019] [Accepted: 06/17/2019] [Indexed: 12/12/2022]
|
8
|
Orf239342 from the mushroom Agaricus bisporus is a mannose binding protein. Biochem Biophys Res Commun 2019; 515:99-103. [PMID: 31128918 DOI: 10.1016/j.bbrc.2019.05.107] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Accepted: 05/16/2019] [Indexed: 12/18/2022]
Abstract
A recently discovered lectin-like protein from mushroom tyrosinase designated as orf239342 inhibits proliferation of the MCF-7 breast cancer cells. This characteristic is likely derived from its ability to recognize sugar entity on the cell surface. Thereby, the binding specificity of orf239342 to sugars was studied. Orf239342 was found to bind specifically to mannose upon analysis with the surface plasmon resonance technique. Finally, our in vitro study showed that mannose impeded orf239342 ability to inhibit proliferation of the MCF-7 breast cancer cells, providing further evidence for the mannose binding onto the protein. Our finding is a breakthrough to characterise orf239342 i.e. to define its functioning in the mushroom, association to the tyrosinase, or even possible application in breast cancer therapy. In addition, the finding allows the more appropriate designation of the protein as Agaricus bisporus mannose binding-protein (AbMb).
Collapse
|
9
|
Diana D, Ismaya WT, Meidianto VF, Tandrasasmita OM, Tjandrawinata RR, Rachmawati H. Bioconjugation of Captopril-Light Subunit of Agaricus bisporus Mushroom Tyrosinase: Characterization and Potential Use as a Drug Carrier for Oral Delivery. Biol Pharm Bull 2018; 41:1837-1842. [PMID: 30259884 DOI: 10.1248/bpb.b18-00553] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We show that a lectin like protein from the mushroom Agaricus bisporus (LSMT) is capable to permeate the epithelial monolayer barrier of the intestine ex vivo. The protein is not toxic or immunogenic upon prolonged administration and elevated dose in mice. Thus, it could be a candidate as a drug carrier for oral administration. However, its permeability should be tested after the protein has been modified, mimicking the condition in which it is used as a drug carrier. The protein was conjugated to captopril, the selected model of a Biopharmaceutical Classification System (BCS) class III drug, with high solubility but poor permeability. The drug was conjugated to LSMT that had been modified with 4-succinimidyloxycarbonyl-alpha-methyl-2-pyridyldithiotoluene (SMPT) as a linker. The success of LSMT modification was confirmed with TLC and MS; the latter also indicated the amount of captopril molecule linked. The modified LSMT could permeate through the intestinal monolayer barrier, and thus could be absorbed in the intestine after modification. The modified protein appears to remain stable after incubation in simulated gastrointestinal fluids. This pioneering work provides an essential basis for further development of the protein as a drug carrier for oral administration.
Collapse
Affiliation(s)
- Diana Diana
- Research group of Pharmaceutics, School of Pharmacy, Bandung Institute of Technology
| | | | | | | | | | - Heni Rachmawati
- Research group of Pharmaceutics, School of Pharmacy, Bandung Institute of Technology.,Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology
| |
Collapse
|
10
|
Ismaya WT, Tandrasasmita OM, Sundari S, Diana, Lai X, Retnoningrum DS, Dijkstra BW, Tjandrawinata RR, Rachmawati H. The light subunit of mushroom Agaricus bisporus tyrosinase: Its biological characteristics and implications. Int J Biol Macromol 2017; 102:308-314. [DOI: 10.1016/j.ijbiomac.2017.04.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 02/16/2017] [Accepted: 04/04/2017] [Indexed: 12/19/2022]
|
11
|
Chatterjee S, Sarma MK, Deb U, Steinhauser G, Walther C, Gupta DK. Mushrooms: from nutrition to mycoremediation. ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH INTERNATIONAL 2017; 24:19480-19493. [PMID: 28770504 DOI: 10.1007/s11356-017-9826-3] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 07/24/2017] [Indexed: 06/07/2023]
Abstract
Mushrooms are well known as important food items. The uses of mushrooms in the cuisine are manifolds and are being utilized for thousands of years in both Oriental and Occidental cultures. Medicinal properties of mushrooms show an immense potential as drugs for the treatment of various diseases as they are rich in a great variety of phytochemicals. In this review, we attempted to encompass the recent knowledge and scientific advancement about mushrooms and their utilization as food or curative properties, along with their natural ability to accumulate (heavy) metals/radionuclides, which leads to an important aspect of bioremediation. However, accumulation of heavy metals and radionuclides from natural or anthropogenic sources also involves potential nutritional hazards upon consumption. These hazards have been pointed out in this review incorporating a selection of the most recently published literature.
Collapse
Affiliation(s)
- Soumya Chatterjee
- Defence Research Laboratory, DRDO, Post Bag No. 02, Tezpur, Assam, 784001, India
| | - Mukul K Sarma
- Defence Research Laboratory, DRDO, Post Bag No. 02, Tezpur, Assam, 784001, India
| | - Utsab Deb
- Defence Research Laboratory, DRDO, Post Bag No. 02, Tezpur, Assam, 784001, India
| | - Georg Steinhauser
- Gottfried Wilhelm Leibniz Universität Hannover, Institut für Radioökologie und Strahlenschutz (IRS), Herrenhäuser Str. 2, 30419, Hannover, Germany
| | - Clemens Walther
- Gottfried Wilhelm Leibniz Universität Hannover, Institut für Radioökologie und Strahlenschutz (IRS), Herrenhäuser Str. 2, 30419, Hannover, Germany
| | - Dharmendra K Gupta
- Gottfried Wilhelm Leibniz Universität Hannover, Institut für Radioökologie und Strahlenschutz (IRS), Herrenhäuser Str. 2, 30419, Hannover, Germany.
| |
Collapse
|
12
|
Ismaya WT, Efthyani A, Tjandrawinata RR, Rachmawati H. Biological responses in Balb/c mice after long-term parenteral administration of the light subunit of mushroom tyrosinase. J Biochem Mol Toxicol 2017; 31. [PMID: 28700109 DOI: 10.1002/jbt.21958] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Revised: 06/12/2017] [Accepted: 06/21/2017] [Indexed: 12/22/2022]
Abstract
Light subunit of mushroom tyrosinase (LSMT) is a protein of unknown function from mushroom Agaricus bisporus that has been demonstrated to permeate through rat intestine ex vivo. Thus, it can be absorbed in the intestine, thereby holding a promise as a drug carrier for oral administration, similar to HA-33 protein from botulinum, one of the closest structural homologs of LSMT. However, the safety of LSMT should be ensured prior to its use. Here, we described biological response of LSMT upon weekly intraperitoneal administration of 50 μg/day to the Balb/c mice for 12 weeks. Motoric and behavior profiles, as well as the index of main organs (liver, spleen, lung, heart, and kidney), and body weight, were not significantly changed as compared with the control group. Also, no IgG was detected in the serum. The results suggest that LSMT is safe for further development.
Collapse
Affiliation(s)
- Wangsa T Ismaya
- Dexa Laboratories of Biomolecular Sciences, JABABEKA II Industrial Estate, Cikarang, 17550, Indonesia
| | - Alida Efthyani
- School of Pharmacy, Institut Teknologi Bandung, Bandung, 40132, Indonesia
| | - Raymond R Tjandrawinata
- Dexa Laboratories of Biomolecular Sciences, JABABEKA II Industrial Estate, Cikarang, 17550, Indonesia
| | - Heni Rachmawati
- School of Pharmacy, Institut Teknologi Bandung, Bandung, 40132, Indonesia.,Research Center for Nanosciences and Nanotechnology, Institut Teknologi Bandung, Bandung, 40132, Indonesia
| |
Collapse
|
13
|
A novel immune-tolerable and permeable lectin-like protein from mushroom Agaricus bisporus. Biochem Biophys Res Commun 2016; 473:1090-1093. [PMID: 27060548 DOI: 10.1016/j.bbrc.2016.04.020] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Accepted: 04/05/2016] [Indexed: 11/21/2022]
Abstract
A lectin like protein designated as LSMT is recently discovered in Agaricus bisporus. The protein adopts very similar structure to Ricin-B like lectin from Clitocybe nebularis (CNL) and HA-33 from Clostridium botulinum (HA-33), which both recognize sugar molecules that decorate the surface of the epithelial cells of the intestine. A preliminary study in silico pointed out potential capability of LSMT to perform such biological activity. Following that hypothesis, we demonstrated that LSMT is indeed capable of penetrating out from a dialysis tube of the mice intestine origin. Furthermore, the protein appeared not to evoke the immune response upon introduction into mice, unlike its structural homologs. This is the first report on the biological implication of LSMT that might lead to its application.
Collapse
|